iosBio’s vaccines and therapeutics use viral vector technology
This is where a harmless virus (in the case of OraPro, a non-replicating adenovirus) is genetically engineered to carry some of the genetic material from the pathogen, e.g. Covid-19, against which immunity is created. When administered, the viral vector vaccine causes the body’s own cells to manufacture proteins from the target pathogen, provoking an immune response and stimulating the production of antibodies and T-cells. This means that when the body is exposed to the real pathogen, it already has the tools it needs to combat the infection.
iosBio’s technology is unique in that it uses our proprietary thermal stability excipients to deliver a viral vector vaccine that is thermally stable at room temperature. This not only transforms the distribution process by removing the cold chain, it also enables fast and easy oral delivery, removing the healthcare professional and the needle from the administration process.
This platform is OraPro.